Avita Medical Inc. (NASDAQ:RCEL) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Avita Medical Inc. (NASDAQ:RCEL) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $13.40.

RCEL has been the subject of several analyst reports. Wall Street Zen upgraded Avita Medical from a “sell” rating to a “hold” rating in a report on Sunday, August 2nd. Lake Street Capital lifted their price objective on Avita Medical from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, August 28th. TD Cowen reissued a “buy” rating on shares of Avita Medical in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avita Medical in a research report on Monday, September 21st. Finally, BTIG Research raised their price objective on Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday.

Avita Medical Stock Performance

Avita Medical stock opened at $16.59 on Monday. The firm has a market cap of $510.64 million, a PE ratio of -14.06 and a beta of 2.03. Avita Medical has a twelve month low of $3.22 and a twelve month high of $18.07. The firm’s 50 day moving average price is $12.77 and its two-hundred day moving average price is $6.85.

Avita Medical (NASDAQ:RCEL) last released its earnings results on Thursday, November 5th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. The firm had revenue of $26.11 million during the quarter, compared to the consensus estimate of $22.35 million. Equities analysts anticipate that Avita Medical will post -0.98 EPS for the current fiscal year.

Avita Medical News Roundup

Here are the key news stories impacting Avita Medical this week:

• Positive Sentiment: Raised revenue outlook: Avita lifted its full-year 2026 revenue guidance, signaling improved expectations for growth. AVITA Medical Raises Revenue Guidance
• Positive Sentiment: Q3 beat estimates: The company reported revenue of $26.11 million, above the $22.35 million analyst consensus, and a loss of $0.20 per share, narrower than the expected $0.24 loss. Another report said revenue surged 53% year over year. AVITA Medical Reports Third Quarter Results Q3 Revenue Growth
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $15 to $21 and maintained a Buy rating, reflecting greater potential upside in its assessment. BTIG Raises Price Target
• Positive Sentiment: Medicare billing changes: A national physician payment framework and simplified billing codes for RECELL procedures are scheduled for 2027. These changes could ease billing complexity and support broader procedure adoption. Medicare Payment Framework and Billing Codes

Hedge Funds Weigh In On Avita Medical

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Avita Medical during the second quarter worth about $2,333,000. NewEdge Advisors LLC lifted its holdings in shares of Avita Medical by 71.4% during the second quarter. NewEdge Advisors LLC now owns 148,931 shares of the company’s stock valued at $615,000 after purchasing an additional 62,046 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Avita Medical by 145.3% during the 1st quarter. Bank of America Corp DE now owns 62,128 shares of the company’s stock valued at $230,000 after buying an additional 36,799 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Avita Medical by 47.7% during the third quarter. Russell Investments Group Ltd. now owns 41,449 shares of the company’s stock valued at $486,000 after purchasing an additional 13,395 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new stake in Avita Medical in the third quarter valued at $440,000. Institutional investors and hedge funds own 27.66% of the company’s stock.

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.